These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23319024)

  • 1. Successful treatment of digital tip necrosis in rheumatoid vasculitis with anti-CD20 antibody rituximab.
    Korkosz M; Królczyk J; Telesińska-Jasiówka D; Grodzicki T
    J Clin Rheumatol; 2013 Jan; 19(1):43-5. PubMed ID: 23319024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of rheumatoid vasculitis-associated skin ulcer with a TNF-α antagonist.
    Ashida A; Murata H; Mikoshiba Y; Ohashi A; Kobayashi A; Koga H; Uhara H; Okuyama R
    Int J Dermatol; 2014 Feb; 53(2):e154-6. PubMed ID: 23557520
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
    Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E
    Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry.
    Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X;
    Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful use of rituximab in recalcitrant skin predominant dermatomyositis.
    Joshi N; Nautiyal A; Davies PG
    J Clin Rheumatol; 2011 Mar; 17(2):111-2. PubMed ID: 21364354
    [No Abstract]   [Full Text] [Related]  

  • 7. Toxic epidermal necrolysis due to therapy with cyclophosphamide and mesna. A case report of a patient with seronegative rheumatoid arthritis and rheumatoid vasculitis.
    Chowdhury AC; Misra DP; Patro PS; Agarwal V
    Z Rheumatol; 2016 Mar; 75(2):200-2. PubMed ID: 26555550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Belmonte Serrano MA; Pincus T
    Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry).
    Glace B; Gottenberg JE; Mariette X; Philippe R; Pereira B; Lequerré T; Berthelot JM; Dougados M; Toussirot E; Pham T; Allanore Y; Loeuille D; Euller-Ziegler L; Soubrier M
    Ann Rheum Dis; 2012 Aug; 71(8):1429-31. PubMed ID: 22504557
    [No Abstract]   [Full Text] [Related]  

  • 10. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New onset of rheumatoid vasculitis during abatacept therapy and subsequent improvement after rituximab.
    Carvajal Alegria G; Uguen A; Genestet S; Marcorelles P; Saraux A; Cornec D
    Joint Bone Spine; 2016 Oct; 83(5):605-6. PubMed ID: 27052429
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis.
    Sumida K; Ubara Y; Takemoto F; Takaichi K
    Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S133. PubMed ID: 21385558
    [No Abstract]   [Full Text] [Related]  

  • 13. Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis.
    Iijima T; Suwabe T; Sumida K; Hayami N; Hiramatsu R; Hasegawa E; Yamanouchi M; Hoshino J; Sawa N; Takaichi K; Oohashi K; Fujii T; Ubara Y
    Mod Rheumatol; 2015 Jan; 25(1):138-42. PubMed ID: 24533557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis.
    Iaccheri B; Androudi S; Bocci EB; Gerli R; Cagini C; Fiore T
    Ocul Immunol Inflamm; 2010 Jun; 18(3):223-5. PubMed ID: 20482403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of rheumatoid vasculitis with acquired reactive perforating collagenosis.
    Ikeda T; Mikita N; Furukawa F; Iwahashi Y
    Mod Rheumatol; 2019 May; 29(3):547-550. PubMed ID: 27846744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rapid efficacy of abatacept in a patient with rheumatoid vasculitis.
    Fujii W; Kohno M; Ishino H; Nakabayashi A; Fujioka K; Kida T; Nagahara H; Murakami K; Nakamura K; Seno T; Yamamoto A; Kawahito Y
    Mod Rheumatol; 2012 Aug; 22(4):630-4. PubMed ID: 22124545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity.
    Kormelink TG; Tekstra J; Thurlings RM; Boumans MH; Vos K; Tak PP; Bijlsma JW; Lafeber FP; Redegeld FA; van Roon JA
    Ann Rheum Dis; 2010 Dec; 69(12):2137-44. PubMed ID: 20679475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.
    Merkesdal S; Kirchhoff T; Wolka D; Ladinek G; Kielhorn A; Rubbert-Roth A
    Eur J Health Econ; 2010 Feb; 11(1):95-104. PubMed ID: 19967426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.